Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore’s TauRx Chief Says Alzheimer’s Disease Candidate May Enter Phase III Trials Soon

This article was originally published in PharmAsia News

Executive Summary

Phase III testing is gathering pace on novel drugs targeting tau buildup, the head of Singapore-based TauRx says, adding that the company has enough cash on hand to complete a Phase III study for an Alzheimer’s treatment that has eluded major drug companies focused on amyloids.

You may also be interested in...



A Silver Lining In Lilly’s Solanezumab Alzheimer’s Failure?

Drug fails all primary endpoints in two Phase III studies, following in the footsteps of Pfizer/Janssen’s bapineuzumab. But Lilly points to a secondary signal in pooled data as a sign of some effect on cognitive decline.

Elan Sets Up For Sale With Neotope Biosciences Spinout

Elan’s sole near-term growth prospect is Tysabri after the Irish drug maker spins out its discovery research unit Neotope Biosciences with $120 million to $130 million in start-up capital.

Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s

As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel